Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

NCT00403000

Prostate Cancer

COMPLETED PHASE2

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

NCT00553878

Prostate Cancer

COMPLETED PHASE2/PHASE3

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

NCT00363311

Neoplasms, Prostate

COMPLETED PHASE4

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924

Prostate Cancer (Adenocarcinoma)

RECRUITING PHASE3

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

NCT00056407

Neoplasms, Prostate

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We have shown in a murine model of treatment with intermittent androgen ablation therapy of prostate cancer that when dutasteride is given during the regrowth phase (off-phase) of intermittent therapy, that tumor growth is inhibited and that survival is improved. We have also shown that testosterone is a more potent inducer of certain tumor suppressor androgen response genes than dihydrotestosterone. In this murine model, we showed that use of a 5-alpha reductase inhibitor (dutasteride) resulted in significant hyperinduction of the U19 tumor suppressor androgen response gene during the regrowth phase of treatment. In the current clinical trial, we will determine if use of dutasteride in men with advanced prostate cancer during the off-phase of intermittent androgen ablation therapy will also result in hyperinduction of these tumor suppressor androgen response genes. Gene expression will be measured in tumor tissue obtained by prostate biopsies during the off-phase when the testosterone level has normalized. Prostate-specific antigen (PSA) levels will also be measured to determine the PSA doubling time during the off-phase to determine the effect of dutasteride on PSA kinetics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A: Dutasteride During First Off-Cycle

Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle

Group Type EXPERIMENTAL

Dutasteride

Intervention Type DRUG

0.5 mg capsule given orally on daily basis

B: Placebo During First Off-Cycle

Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Identical placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dutasteride

0.5 mg capsule given orally on daily basis

Intervention Type DRUG

Placebo

Identical placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avodart

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven prostate cancer
* Patients are hormone-naive
* Patients either to begin androgen ablation therapy with luteinizing hormone-releasing hormone (LHRH) agonist or already receiving therapy with LHRH agonist
* Advanced prostate cancer with either positive pelvic nodes or bone/visceral metastasis
* Must have an intact prostate (no previous surgery or XRT)
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Recovery from any major infection or surgical procedure
* Signed informed consent

Exclusion Criteria

* Known intolerance or allergy to dutasteride
* Concomitant chemotherapy, biologic therapy, or XRT to prostate
* Bilateral orchiectomy
* Prior malignancy within 5 years of registration

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No